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Abstract
Background: The aggregation of amyloid-β (Aβ) into insoluble plaques is a hallmark pathology of Alzheimer’s
disease (AD). Previous work has shown increasing serotonin levels with selective serotonin re-uptake inhibitor (SSRI)
compounds reduces Aβ in the brain interstitial fluid (ISF) in a mouse model of AD and in the cerebrospinal fluid of
humans. We investigated which serotonin receptor (5-HTR) subtypes and downstream effectors were responsible
for this reduction.
Results: Agonists of 5-HT4R, 5-HT6R, and 5-HT7R significantly reduced ISF Aβ, but agonists of other receptor
subtypes did not. Additionally, inhibition of Protein Kinase A (PKA) blocked the effects of citalopram, an SSRI,
on ISF Aβ levels. Serotonin signaling does not appear to change gene expression to reduce Aβ levels in
acute timeframes, but likely acts within the cytoplasm to increase α-secretase enzymatic activity. Broad
pharmacological inhibition of putative α-secretases increased ISF Aβ and blocked the effects of citalopram.
Conclusions: In total, these studies map the major signaling components linking serotonin receptors to
suppression of brain ISF Aβ. These results suggest the reduction in ISF Aβ is mediated by a select group of
5-HTRs and open future avenues for targeted therapy of AD.
Keywords: Alzheimer’s Disease, beta-amyloid, Serotonin receptor, SSRI, Microdialysis, PKA, α-secretase
Background
One primary pathology of Alzheimer’s disease (AD) is
the accumulation of insoluble amyloid-β (Aβ) plaques in
the brain. Aβ is produced by sequential cleavage of the
amyloid precursor protein (APP) by β- and γ-secretases
[1, 2]. Alternatively, activity of another type of enzymes,
α-secretases, can cleave within the Aβ sequence and pre-
vent its formation [3]. Concentration is a key factor that
determines whether soluble Aβ peptide aggregates into
oligomers and plaques [4, 5], with higher concentrations
increasing the likelihood that toxic multimers of Aβ will
form. Consequently, reducing Aβ levels is one promising
target for AD therapy.
Serotonin, Aβ, and AD have been connected in several
studies in the scientific literature. The amount of both
serotonin (5-HT) and its receptors (5-HTRs) are reduced
in human post-mortem AD studies [6, 7]. Serotonergic ac-
tivity reduces Aβ production rates in vitro and 5-HTR ag-
onists alter APP processing to increase soluble fragments
of the protein that are consistent with a suppression in Aβ
generation [8–11]. Manipulating serotonin levels in vivo
shows similar effects. In our previous work, treating
APPswe/PS1ΔE9 (APP/PS1) mice with a single dose of a
selective serotonin re-uptake inhibitor (SSRI) reduced
brain interstitial fluid (ISF) Aβ concentrations by 25 %
[12]. Serotonin treatment did not alter the Aβ elimination
rate which suggests this reduction was not mediated by
Aβ clearance mechanisms. Instead, α-secretase enzymatic
activity was increased by SSRI treatment, suggesting that
Aβ generation was suppressed. Chronic dosing with a
SSRI over 4 months reduced brain Aβ plaque load and
cerebrospinal fluid (CSF) Aβ levels in mice by 50 % [12].
Similar reductions in Aβ were seen by SSRI treatment of
3xTg AD mouse model [6]. The reduction in Aβ by SSRI
is not limited to mice; young adult, cognitively normal,
non-depressed individuals given a single dose of the SSRI
citalopram also showed a reduction in CSF Aβ levels in a
matter of hours [13].
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The cellular mechanism of SSRI-induced Aβ reduction
is likely complex. There are 15 identified serotonin recep-
tors expressed in the brain [14]. Most 5-HTRs are G-
protein coupled receptors (GPCRs) while 5-HT3R is the
only ionotropic cation channel [15]. 5-HT1R and 5-HT5R
couple to Gi/o signal proteins and typically lead to Protein
Kinase C (PKC) activation [16–18] while 5-HT2R signals
through Gq proteins to activate calcium-calmodulin
dependent kinase II (CaMKII) [15, 19]. 5-HT4R, 5-HT6R,
and 5-HT7R activate Gs proteins, which usually increase
cyclic AMP levels, and induce Protein Kinase A (PKA)
activation [10, 15, 20]. Interestingly, stimulating some
serotonin receptors can activate the extracellular signal-
regulated kinase (ERK) [18, 20–22]. Inhibition of MAP
kinase-ERK kinase (MEK), the kinase that activates ERK,
reduces the production of the α-secretase cleavage prod-
uct sAPPα in vitro [23]. Also, inhibiting either ERK or
MEK increased ISF Aβ levels in mice and blocked the
SSRI-dependent reduction in Aβ [12]. Our current study
shows serotonin-induced reductions of Aβ, rely on the
Gs-linked serotonin receptors and PKA signaling. We also
provide evidence that serotonergic-dependent suppression
of Aβ is mediated through an increase in α-secretase en-
zymatic activity.
Results
Serotonin-induced reduction in ISF Aβ is receptor specific
Aβ is largely produced by neurons during synaptic activity
and is continually released into the ISF [24–27]. We used
in vivo brain microdialysis to measure dynamic changes in
ISF Aβ levels [28]. This method allows for serial collection
of ISF Aβ every hour over the course of several days from
awake and freely mobile mice [24]. Small molecule com-
pounds can be administered by intraperitoneal (i.p.) injec-
tion or by infusing the agents directly into the brain via the
microdialysis probe, a method called reverse microdialysis
when agents cross the membrane and act locally around
the probe. Local infusion circumvents the blood brain bar-
rier and allows for continual administration over time.
We previously showed that treating mice with several
SSRIs caused a 25 % decrease in ISF Aβ [12]. SSRI com-
pounds are not selective for a specific 5-HTR; they com-
pete with 5-HT for binding to the serotonin reuptake
transporter which increases 5-HT concentrations [29],
thus activating all serotonin receptors present. The
SSRI-dependent reduction in brain Aβ requires ERK ac-
tivation, and stimulation of 5-HTRs can stimulate ERK
under certain conditions [12, 18, 20–22]. These results
suggest that any or all of the 15 different 5-HTRs could
be responsible for the reduction in ISF Aβ. To determine
the role of individual receptors, we administered a se-
lective 5-HTR agonist for each receptor class by reverse
microdialysis. Two to three month old APP/PS1 mice
[30] were implanted with unilateral microdialysis probes
in the hippocampus. Mice at this age do not yet show
Aβ plaques which enabled us to study normal Aβ me-
tabolism without the added variable of Aβ pathology
[28, 31, 32]. Basal levels of ISF Aβ were evaluated for 9 h
before treatment with selective 5-HTR agonists by re-
verse microdialysis (see Table 1 for dosages). Treatment
Table 1 Pharmacological agents used for reverse microdialysis
Compound Target IC50 or Ki Rev MD Concentration Dosage Across MD Membrane Selectivity Limit Reference
Agonists
Ipsapirone 5-HT1AR 10 nM 1 μM 100 nM 58 nM
a [59]
WAY161503 5-HT2CR 4 nM 400 nM 40 nM 233 nM [60]
ML10302 5-HT4R 4 nM 400 nM 40 nM 700 nM [61]
ST1936 5-HT6R 13 nM 1.3 μM 130 nM 168 nM [62]
AS19 5-HT7R 0.83 nM 83 nM 8.3 nM 6.6 nM
b [63]
Antagonists
GR113808 5-HT4R 0.02 nM 100 nM 10 nM 10 μM [64]
SB258719 5-HT7R 31.6 nM 3.16 μM 316 nM 316 nM [68]
Inhibitors
GM6001 ADAM/MMP 0.5 nM-27 nM 2.5 μM 250 nM NA [66]
KT5720 PKA 60 nM 6 μM 600 nM 2 μM [67]
PKI14-22 PKA 36 nM 3.6 μM 360 nM 15 μM [65]
All agents were chosen for their selectivity for their targets as assayed in previous literature. We used the Ki and IC50 values to determine necessary
concentrations of each compound (reverse microdialysis (Rev MD) concentration). We assumed only 10 % of the drug would cross the membrane (Dosage Across
MD membrane), and this amount of the compound would be further diluted in the brain ISF. The selectivity limit is the concentration above which each
compound begins stimulating off-target receptors
aIpsapirone has been shown to stimulate bovine α-adrenergic receptors at 58 nM in vitro [59]
bAS19 can stimulate 5-HT1DR at 6.6 nM concentrations in vitro [63]. However, expression of this receptor is absent in adult mouse hippocampus [14], so effects of
its stimulation should be neglible
Abbreviations: 5-HTR serotonin receptor, ADAM a disintegrin and metallopeptidase domain, MMP matrix metallopeptidase, PKA protein kinase A
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with a selective agonist for 5-HT4R, 5-HT6R, or 5-HT7R
significantly reduced ISF Aβ40 by approximately 25 %.
Each of these three receptors was equally effective at
lowering Aβ. Interestingly, reductions by each agonist
alone are equivalent to reduction induced by 5-HT or
citalopram SSRI (Fig. 1a and b), suggesting that each
receptor alone is sufficient to induce the maximal ef-
fect on ISF Aβ. However, treatment with agonists se-
lective for 5-HT1AR or 5-HT2CR did not produce
significant changes in ISF Aβ40 (Fig. 1c and d). These
results suggest that only a subset of 5-HTRs, specific-
ally those that activate Gs-coupled proteins, are likely
responsible for the reduction in ISF Aβ by serotonin.
To ensure that the serotonin-mediated suppression in
ISF Aβ is via a normal metabolic pathway and not an
artifact of APP transgenic over-expression, we admin-
istered citalopram to wildtype, C57Bl6 mice. The SSRI
reduced ISF murine Aβ levels by over 30 % compared
to vehicle, similar to the effect found in transgenic
mice (Fig. 1e).
Fig. 1 A small subset of 5-HT receptors reduce ISF Aβ levels in vivo. Selective agonists for individual 5-HT receptors or vehicle (DMSO) were
infused via reverse microdialysis (rev md) in 2–3 month old APP/PS1 hemizygous mice. a As assessed by microdialysis, broad activation of 5-HTRs
by serotonin (2 mM by rev md) directly or by citalopram (10 mg/kg i.p.), a SSRI, caused a decrease in ISF Aβ levels. Similarly, reverse microdialysis
treatment with agonists for 5-HT4R (ML10302, 400 nM), 5-HT6R (ST1936, 1.3 μM), and 5-HT7R (AS19, 83 nM) induced a reduction in ISF Aβ in living
mice. b After hours 22-24 of continuous treatment, ML10302, ST1936, and AS19 reduced ISF Aβx-40 by 25.2 ± 3.4 % (p < 0.01; n = 6), by 24.8 ±
6.1 % (p < 0.01; n = 6), and by 22.5 ± 5.5 % (p < 0.05; n = 6), respectively. Serotonin and citalopram also significantly reduced ISF Aβ by 26.5 ± 5.4 %
(p < 0.01; n = 7) and 25.5 ± 3.4 % (p < 0.05; n = 5), respectively. c Agonist treatment for 5-HT1AR (Ipsapirone, 1 μM) or 5-HT2CR (WAY161503, 400
nM) showed no significant reduction of ISF Aβ. d After 24 h of continuous treatment, Ipsapirone reduced ISF Aβx-40 to 91.2 ± 9.4 % (n = 6) and
WAY161503 increased ISF Aβx-40 to 119.9 ± 8.6 % (n = 8). e Citalopram (10 mg/kg, i.p.) administered to young C57Bl6 wildtype mice significantly
reduced ISF Aβ levels by 32 ± 4.2 % at 21–24 h after treatment compared to vehicle-treated (PBS) mice (p < 0.001; n = 6). f Mice were treated with
selective 5-HT7R antagonist SB258719 (3.16 μM) for 8 h followed by co-administration of 5-HT7R agonist, AS19, (83nM) for 24 h by reverse microdialysis
(n = 4). The antagonist completely blocked the effect of the agonist. The antagonist alone had no significant effect on ISF Aβ levels. Data presented as
mean ± SEM. Asterisks mark p-values < 0.05; double asterisks mark p-values < 0.01; triple asterisks mark p-values 0.001
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The dose of each agonist was 5-175 times more selective
for their targets than other receptor types. We estimate that
only 10 % of each compound crosses the microdialysis
membrane; however, this varies based on drug properties
so we cannot rule out some off-target effects of these com-
pounds. The concentration of 5-HT1AR agonist we used in
this experiment could possibly activate α-adrenergic recep-
tors, though we saw no reduction in Aβ levels like those
seen with the potent adrenergic receptor agonist caffeine
[33]. To verify that the reductions in ISF Aβ were indeed to
due to 5-HTR activation, we co-administered a 5-HT7R an-
tagonist and agonist to APP/PS1 mice (Fig. 1f). Pretreat-
ment with the antagonist completely blocked the reduction
in ISF Aβ by the agonist, demonstrating the specificity of
this suppression in ISF Aβ is due to those receptors.
Citalopram also significantly reduced soluble APPα
(sAPPα) levels in the ISF of young APP/PS1 by 17.4 ±
4.0 % (p <0.05) as assessed with 1,000 kDa MWCO mi-
crodialysis probes and assessed by Western blotting
(Additional file 1: Figure S1). However, the SSRI had no
effect on ISF Aβ oligomers in these young mice
(Additional file 1: Figure S2).
Selective 5-HTR antagonists increase ISF Aβ
If 5-HT4R, 5-HT6R, and 5-HT7R mediated the reduction
in ISF Aβ, then we postulated that blocking their activity
may have the opposite effect. To test this hypothesis, we
administered GR113808 and SB258719, selective antago-
nists for 5-HT4R and 5-HT7R respectively, alone or in
combination via reverse microdialysis (Fig. 2a). We
chose to examine 5-HT4R and 5-HT7R as there is evi-
dence their expression is reduced with increasing age
[34]. Antagonizing a single receptor did not significantly
change Aβ40 levels after 24 h of administration. How-
ever, blocking both receptors caused a significant in-
crease of 32 % in ISF Aβ40 (Fig. 2b). Taken together with
data from Fig. 1a, our results demonstrate that basal
activity of 5-HT4R and 5-HT7R is normally suppressing
Aβ levels, but stimulated activity of only one receptor at
a time is sufficient to reduce Aβ levels in acute time
frames. This suggests there is a redundancy to 5-HT sig-
naling that is capable of lowering Aβ levels.
Inhibition of PKA activity increases ISF Aβ levels
The strong effects of 5-HT4R, 5-HT6R, and 5-HT7R led
us to examine downstream signaling pathways. All three
of these receptors typically activate Gs proteins, increase
cAMP levels, and induce PKA activation [15, 20]. To de-
termine the role of PKA in serotonin-mediated ISF Aβ
reduction, we administered KT5720, a small molecule
selective PKA inhibitor, via reverse microdialysis. Treat-
ment with KT5720 alone for 24 h significantly increased
ISF Aβ levels by 30 %, suggesting PKA has a normal role
in regulating basal ISF Aβ levels (Fig. 3a and b). Our pre-
vious results suggest that 5-HT4R, 5-HT6R, and 5-HT7R
work together to regulate basal ISF Aβ levels; therefore,
we stimulated all receptors with a SSRI in order to ob-
serve the effects of PKA inhibition. The KT5720 inhibi-
tor also blocked the citalopram-dependent decrease in
ISF Aβ levels. To confirm the specificity of the results, we
replicated the experiment with a structurally-distinct PKA
peptide inhibitor, PKI14-22 amide myristoylate [35].
PKI14-22 was pretreated by reverse microdialysis for 8 h,
followed by co-administration of citalopram by i.p. injec-
tion (10 mg/kg). Both inhibitors of PKA completely
blocked the effect of the SSRI (Fig. 3b). These results
strongly suggest PKA activity is required for ISF Aβ reduc-
tion by 5-HT signaling.
Acute SSRI treatment does not change expression of Aβ
metabolism-related genes/proteins
Activation of ERK is one event that can occur down-
stream of PKA signaling [15]. We have previously shown
that pERK levels were elevated after SSRI treatment, and
Fig. 2 Inhibiting 5-HT4R and 5-HT7R simultaneously increases ISF Aβ. Selective 5-HT4R antagonist GR113808 (100 nM), selective 5-HT7R antagonist
SB258719 (3.16 μM), both antagonists together, or DMSO vehicle were infused via reverse microdialysis in 2.5 month old APP/PS1 hemizygous
mice for 8 h. a As assayed by microdialysis, treatment with GR113808 or SB258719 alone had no detectable effect on ISF Aβx-40 (n = 4), but co-
administration of both antagonists increased ISF Aβx-40. b 24 h of treatment with both antagonists significantly increased ISF Aβx-40 to 132 ±
11.2 % (p = 0.048, n = 10) by 21–24 h. Data presented as mean ± SEM. Asterisks mark p-values < 0.05
Fisher et al. Molecular Neurodegeneration  (2016) 11:45 Page 4 of 12
inhibiting the ERK signaling cascade increased ISF Aβ
[12]. Once phosphorylated, activated ERK can trans-
locate to the nucleus to modify nuclear proteins and
suppress gene expression. Interestingly, reductions in
secretase gene expression have been observed with
chronic SSRI therapy in other studies [12, 36]. To deter-
mine if ERK is modifying gene expression to reduce ISF
Aβ in the acute phase, we measured expression of genes
involved in Aβ metabolism following treatment with
citalopram. 2.5 month old APP/PS1 mice were treated
with citalopram by i.p. injection (10 mg/kg) or PBS and
were sacrificed 16 h later. This dosage of SSRI was
enough to reduce ISF Aβ levels (Fig. 1), and 16 h was
the earliest time that reductions in ISF Aβ reached stat-
istical significance after SSRI treatment [12]. We per-
formed quantitative real-time PCR (qPCR) for 34 genes
involved in Aβ metabolism using purified hippocampal
mRNA. Expression of immediate early gene FBJ osteo-
sarcoma oncogene (cFOS) was used as a positive control;
its expression is reduced by citalopram within 24 h [37].
Expression of each gene was normalized to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) and normal-
ized to the mean expression level of PBS-treated
controls. CaMKII was used as the control for statistical
analysis since our previous studies showed that inhib-
ition of its activity had no effect on ISF Aβ levels [38],
and we observed no changes in gene expression by
qPCR. There was no significant change in APP expres-
sion following SSRI treatment. α-secretase (a disintegrin
and metallopeptidase domain 10 (ADAM10), ADAM17,
matrix metallopeptidase 9 (MMP9)), β-secretase (beta-
site APP-cleaving enzyme (BACE1)), and γ-secretase
(anterior pharynx defective 1 (Aph1), basigin, nicastrin,
presenilin 1, presenilin 2, presenilin enhancer 2 (PSEN2))
gene expression were not significantly affected by SSRI.
There was also no altered expression of MMP9, neprilysin,
or low density lipoprotein receptor-related protein 1
(LRP1), three proteins involved with Aβ clearance (Fig. 4a).
There was no significant change in major signaling genes
such as PKA (PKA catalytic unit α (PKA Cα), PKA cata-
lytic unit β (PKA Cβ), PKC (PKCα), CaMKII, MEK, ERK,
or c-Jun N-terminal kinase (JNK). Expression of β-arrestin
2, an important scaffolding protein for many signaling
pathways, showed no change after SSRI treatment. Ex-
pression of serotonin receptors was also not significantly
changed following SSRI treatment (Fig. 4b and c). These
negative results suggest that the acute reductions in ISF
Aβ following citalopram treatment are unlikely to be me-
diated by changes in expression of genes linked to Aβ
metabolism.
We also performed Western blots for several putative
α-secretase proteins (ADAM10, ADAM17, MMP2) in
hippocampi from mice treated with citalopram for 16 h
(Additional file 1: Figure S3). We did not find any
change in expression levels for these proteins in whole
tissue extracts; however, we cannot discount the possi-
bility of altered sub-cellular localization of these proteins
or that their enzymatic activity could be enhanced [12]
despite no change in expression.
α-secretase mediates the serotonin-induced reduction in
ISF Aβ
We previously showed that α-secretase enzymatic activity
was increased by SSRI while β-secretase activity was un-
changed [12]. Also there was no difference in Aβ half-life
after SSRI treatment which suggests that Aβ clearance
was unaffected [12]. These results suggest the reduction of
ISF Aβ by serotonin is induced by reducing Aβ produc-
tion. Similar to other neurotransmitter receptors, we
hypothesized that increased α-secretase activity may medi-
ate this suppression of Aβ [38–40]. Several proteins
demonstrate α-secretase enzymatic activity in vitro such
as ADAM10, ADAM17, and MMP9 [3, 41, 42]. The
Fig. 3 PKA activity modulates production of ISF Aβ. a Selective small
molecule inhibitor KT5720 (6 μM), peptide inhibitor PKI14-22 amide
(3.6 μM), or vehicle (DMSO or acetonitrile, respectively) were infused via
reverse microdialysis (rev md) in 2.5 month old APP/PS1 hemizygous
mice for 24 h. In two cohorts of mice after 8 h of inhibitor treatment,
the SSRI citalopram was administered by i.p. injection at 10 mg/kg.
b Inhibiting PKA with KT5720 alone for 24 h caused a significant
increase in ISF Aβx-40 levels by 31.9 ± 6.0 % (p < 0.05; n= 4). By 16 h after
co-administration of citalopram with either KT5720 or PKI 14-22, ISF
Aβx-40 levels were significantly increased by 45.8 ± 10.5 % (p < 0.05, n=
6) and by 50.6 ± 19.6 % (p < 0.05, n= 6), respectively. Most importantly,
each inhibitor completely blocked the effect of citalopram on ISF Aβ
levels. Data represented as mean ± SEM. Asterisks mark p-values < 0.05
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presence of multiple α-secretase enzymes can generate
redundancy; therefore, inhibiting a single candidate may
not stop all enzyme activity [43, 44]. Consequently, we
administered the broad spectrum ADAM/MMP inhibitor,
GM6001, by reverse microdialysis for 8 h and then co-
administered citalopram by i.p. injection. Treatment with
25 μM GM6001 induced a dramatic increase in ISF Aβ,
but levels stabilized near 260 % of baseline after a few
hours (Fig. 5a). However, ISF Aβ levels for GM6001-
treated mice were not significantly reduced after 16 h of
citalopram treatment (Fig. 5b), suggesting that serotonin-
induced reduction in ISF Aβ is mediated by α-secretase
enzymatic activity.
Discussion
We found that only a subset of 5-HTRs are required to
suppress brain Aβ levels in vivo. Serotonin receptors
that activate PKA subsequently activate ERK to increase
α-secretase enzymatic activity. This increased activity
cleaves APP within the Aβ sequence to suppress brain
ISF Aβ levels.
Fig. 4 Acute SSRI treatment has no significant effect on expression of
Aβ APP metabolism genes. 2.5 month old APP/PS1 hemizygous mice
were treated with 10 mg/kg citalopram or PBS by i.p. injection. 16 h later
hippocampi were microdissected for qPCR analysis. a qPCR analysis for
genes involved in Aβ processing or clearance showed no significant
changes in expression. In contrast, the positive control, cFos, was
significantly reduced to 57.5 ± 0.04 % (p< 0.05). b qPCR analysis for
genes encoding signaling proteins downstream of 5-HTR showed no
significant changes in expression. c qPCR analysis for 5-HTR genes
showed no significant changes in expression. Data are presented as
mean ± SEM. Values are normalized to the mean expression level of the
PBS controls (n = 6). Statistical significance was calculated by
one-way ANOVA with comparison to CaMKII and corrected for
multiple comparisons. Asterisks mark p-values < 0.05. See
Additional file 1 for primer sequences and database numbers
Fig. 5 Broad spectrum inhibition of α-secretase enzymes blocks the
effects of SSRI. Broad spectrum ADAM/MMP inhibitor GM6001 (25 μM) or
vehicle (DMSO) was infused via reverse microdialysis in 2.5 month old
APP/PS1 hemizygous mice. 8 h later, the SSRI citalopram was administered
by i.p. injection at 10 mg/kg. a As assessed by microdialysis, inhibiting
ADAM/MMP enzymes dramatically increased ISF Aβx-40 levels, but there
was no reduction in ISF Aβ after SSRI. b After 16 h, vehicle control with
SSRI significantly reduced ISF Aβx-40 to 80.9 ± 2.4 % (p= 0.002, n=6) of
levels at hour 8. GM6001 treatment increased ISF Aβx-40 to 264.2 ± 21.1 %
at time point 8. After 16 h of SSRI treatment, GM6001 ISF Aβx-40 levels
were unchanged at 254.9 ± 16.3 % of baseline (p= 0.74, n= 6). Data
represented as mean± SEM. Asterisks mark p-values < 0.05
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ISF Aβ levels are reduced by specific 5-HTRs signaling
through PKA
Stimulation of serotonin receptors with SSRI antidepres-
sants reduces brain ISF Aβ by 25 % in APP/PS1 trans-
genic mice [12]. As SSRI compounds are not selective
for a specific 5-HTR, therefore any or all of the recep-
tors could reduce ISF Aβ. In this study we demonstrate
that stimulation of 5-HT4R, 5-HT6R, and 5-HT7R with
selective agonists significantly lowered ISF Aβ while ago-
nists for other 5-HTR subtypes did not (Fig. 1). Interest-
ingly, the magnitude of reduction by 5-HT4R, 5-HT6R,
or 5-HT7R activity alone was equal to the reduction in-
duced by serotonin or SSRI. Further, blocking activity of
one receptor has no effect on Aβ; blocking two of these
receptors together is necessary to increase ISF Aβ (Figs. 1
and 2). This suggests there is a redundancy and compen-
sation in the serotonin signaling pathway that is capable
of suppressing Aβ generation. These results suggest that
activity of only three 5-HTRs are primarily responsible
for the reduction in Aβ after SSRI treatment. Our data
are consistent with previous findings in the literature.
Tesseur et al. showed 1 month treatment with a 5-HT4R
selective agonist reduced soluble Aβ40 and plaque load
in the hippocampus [45]. Also, Gianonni et al. showed
therapy with a weak 5-HT4R agonist increased concen-
trations of the α-secretase product and reduced plaque
load in 5xFAD mice [46]. 5-HTR subtypes 4, 6 and 7 are
Gs-linked receptors that typically activate PKA. Tesseur
et al. reported that 5-HT4Rs activate phospholipase C
(PLC) to reduce Aβ levels [45]; further studies are neces-
sary to determine if PKA and PLC work in concert or
are mutually-exclusive pathways to modulate Aβ levels.
It is worth noting that we used agonists for 5-HT 1A,
2C, 4, 6, and 7 receptors as representatives for each
class. However, we cannot draw absolute conclusions
whether other 5-HTR subtypes may have similar or even
contrary effects on Aβ levels. Additionally, activation of 5-
HT2CR had a trend to increase ISF Aβ levels (p = 0.0625),
suggesting that other receptor subtypes may have the
opposite effect on ISF Aβ. Whether or not other 5-HT re-
ceptors have opposing effects on Aβ remains to be
explored. It is important to note the limitation that few
compounds tested had a full dose–response per-
formed to determine their most effective dose in vivo.
Most of these selective compounds begin stimulating
off-target receptors above a specific concentration.
For example, a higher dosage for the 5-HT 1A or 2C
agonists may change ISF Aβ levels, but any effects
would be confounded by these off-target interactions.
Identifying the minimum concentration that reduces
ISF Aβ for each compound would be valuable from a
therapeutic standpoint. However, the primary focus of
this study was 5-HT signaling pathways instead of AD
therapy.
5-HTR subtypes 4, 6 and 7 activate Gs proteins, typic-
ally increase cAMP levels, and induce PKA activation
[15, 20]. The strong reduction of ISF Aβ induced by
stimulating these receptors suggests that PKA may be
involved. We showed that inhibition of PKA activity
with two structurally-distinct, selective inhibitors signifi-
cantly increased ISF Aβ and abolished the effects of SSRI
(Fig. 3). This result suggests that PKA activity is necessary
for the reduction in ISF Aβ by serotonergic signaling.
Interestingly, the increase in Aβ after PKA inhibition was
of a similar magnitude to the increase observed after ERK
inhibition [12, 38]. The interactions between these two ki-
nases are complex. Stimulating PKA with serotonin has
been shown to induce ERK activation, but there is evi-
dence that ERK can activate PKA after exposure to brain
derived neurotrophic factor (BDNF) [20, 47]. However,
treating APP/PS1 mice with BDNF had no effect on ISF
Aβ [38]. Further work will be necessary to understand the
relationship between these two kinases following SSRI
treatment.
Citalopram does not change expression of Aβ
metabolism related genes after acute SSRI treatment
We have shown that ERK inhibition raises Aβ and abol-
ishes the effects of citalopram [12]. Generally, ERK can
act within two cellular compartments; ERK can translo-
cate into the nucleus to modify gene expression or can
phosphorylate proteins in the cytoplasm. We saw no sig-
nificant changes in expression in the major genes related
to Aβ metabolism, serotonin receptors, or signaling
pathways 16 h after SSRI treatment (Fig. 4). However,
these results do not necessarily exclude the role of gene
expression in Aβ production after SSRI treatment; other
studies have shown reductions in secretase-related genes
after chronic SSRI administration [12, 45]. However,
those reductions were seen after months of treatment
whereas our data were obtained after only a few hours.
More research is necessary to understand when expres-
sion of Aβ metabolism genes begins to decline after SSRI
treatment and what impact this has on Aβ. The rapid re-
duction in ISF Aβ we observe in the acute timeframe
suggests a post-translational response to alter enzymatic
activity. Additionally, our qPCR data also suggest ERK is
acting outside the nucleus to reduce Aβ.
α-secretase mediates the effects of serotonin-induced
reduction of Aβ
ADAM10 is the constitutive α-secretase protein in
neurons, however ADAM17 and MMP9 can act as α-
secretase as well [3, 41, 42]. Using a broad spectrum in-
hibitor of ADAM and MMP enzymes, GM6001, we
showed that blocking α-secretase enzymatic activity
alone increases ISF Aβ levels rapidly and, more import-
antly for this study, completely blocks the SSRI-
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dependent suppression in ISF Aβ levels (Fig. 5). Admit-
tedly, broadly inhibiting ADAM/MMP proteins with
GM6001 is mechanistically complicated; ADAM/MMP
proteases could affect both Aβ generation and Aβ clear-
ance [3, 48]. However, previous studies [12] have found
citalopram SSRI does not affect Aβ clearance, meaning
the effect here is likely on Aβ production. Unfortunately,
the broad range of targets for GM6001 prevents us from
identifying which α-secretase protease is responsible for
the reduction in ISF Aβ after SSRI. Future studies using
a more targeted approach with selective inhibitor
compounds or genetic manipulation of the putative α-
secretases will be necessary to answer that question.
Interestingly, treatment with a SSRI reduces both ISF
Aβ levels and ISF sAPP-α levels. This result is actually
opposite of what one might expect if serotonin increases
α-secretase activity; however, the sAPP fragments have
their own metabolic pathways that are not fully understood.
The idea that APP cleavage produces a 1:1 relationship be-
tween all the fragments is not necessarily true. We find this
new data intriguing and believe future studies are important
and necessary to uncover the mechanisms are work here.
Our results suggest the simplified model presented in
Fig. 6. Serotonin activates 5-HT4R, 5-HT6R, and 5-HT7R
which then activate PKA. PKA signaling activates MEK
and ERK. We hypothesize that activated ERK phosphor-
ylates an α-secretase in the cytoplasm to increase its
activity and reduce ISF Aβ. There is evidence that phos-
phorylation by ERK can increase α-secretase enzymatic
activity [49]. ERK activation increases cleavage activity of
ADAM17 in vitro, and mutating the putative ERK phos-
phorylation site blocks this increase [50]. Interestingly,
ADAM10 contains a similar ERK consensus site which
suggests it may also be an ERK substrate [51, 52]. Future
research will determine if ERK directly phosphorylates
α-secretase after SSRI exposure.
Activation of 5-HTR subtypes 4, 6, and 7 all reduce
ISF Aβ by ~25 % which is the same amount as either
SSRI treatment or direct 5-HT infusion (Fig. 1a, b). This
suggests that these receptors likely activate a common
signaling pathway, and activity of any of these receptors
is sufficient to fully activate this pathway to suppress Aβ.
Supportive of this hypothesis is that antagonizing one
receptor alone does not change ISF Aβ, but antagonizing
two receptors is necessary to increase Aβ by 30 %
(Fig. 2). This suggests there is functional redundancy to
serotonergic suppression of Aβ generation.
Conclusions
The dramatic reductive effects of SSRIs on Aβ in mice and
humans are encouraging for AD therapy. Millions of
individuals world-wide use SSRIs on a daily basis for
Depression and other disorders; however, these agents are
not without side effects. 5-HTRs can be found throughout
the digestive system [53, 54], and their stimulation by SSRI
therapy can cause unpleasant digestive problems [55]. Also,
stimulation of 5-HT2R in vascular tissue can lead to con-
striction of blood vessels and sexual side effects [55, 56].
Focusing AD therapy on a single or subset of 5-HTRs may
reduce some of the side effects of SSRI treatment. In this
report, we have shown activation of 5-HT4R, 5-HT6R,
and 5-HT7R by selective agonists can significantly re-
duce ISF Aβ in mice by 25 %. In other mouse studies, a
similar reduction of Aβ levels is sufficient to completely
block plaque growth and significantly reduce new
plaque formation [13, 57]. The safety and efficacy of
selective agonists for these receptors need to be tested




All experiment protocols using animals were performed
in accordance to the guidelines established by the Ani-
mal Studies Committee at Washington University. We
bred APPswe/PS1ΔE9 hemizygous mice (Jackson La-
boratory) [58] to wild type C3H/B6 mice and aged the
APP/PS1+/- offspring to 2–3.5 months for experiments.
Fig. 6 Model of Aβ reduction by serotonergic signaling. Serotonin
binding to 5-HT4R, 5-HT6R, and 5-HT7R leads to the activation of
PKA. PKA subsequently activates the MEK and ERK cascade. Activated
ERK remains in the cytoplasm and phosphorylates α-secretase to
increase its activity and reduce Aβ production
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Mice were screened for APPswe and PS1ΔE9 transgenes
by PCR from toe DNA.
Compounds
All pharmaceutical compounds were ordered from
Tocris Biosciences except for serotonin hydrochloride
(Sigma-Aldrich). All compounds delivered by reverse
microdialysis were diluted in microdialysis buffer con-
sisting of artificial cerebrospinal fluid (aCSF) with 0.15-
2 % BSA (Sigma-Aldrich). Specificity of each compound
for its target was established by activity assays against li-
braries of receptors as described in previous literature
[59–68]. The selectivity limit is the concentration above
which the compound begins to stimulate off-target re-
ceptors. Concentrations used took into account the IC50
or Ki for each compound and only 10 % delivery across
the membrane at a 1 μl/min flow rate (Table 1). This
small volume of each compound would be diluted even
further in brain CSF. Agonists are 5-175 times more select-
ive for their targets than other receptor types. Citalopram
hydrobromide (Toronto Research Chemicals) was diluted
in PBS and injected i.p. at 10 mg/kg of body weight.
In vivo Aβ microdialysis
In vivo microdialysis to measure brain ISF Aβ and
sAPP-α in the hippocampus of freely moving APP/PS1
mice was performed similar to previously described
[12, 24, 28]. This method captures soluble molecules
in the extracellular fluid that are below the 30 kDa mo-
lecular weight cutoff of the probes. Under volatile isoflur-
ane anesthetic, guide cannula (BR-style; Bioanalytical
Systems or Atmos; EICOM) were cemented above the left
hippocampus (3.1 mm behind Bregma, 2.5 mm lateral to
midline, and 1.2 mm below dura at a 12° angle). Two
millimeter microdialysis probes were inserted through the
guides so their membranes were completely contained in
the hippocampus (30 kDa BR-2; Bioanalytical Systems;
1,000 kDa AtmosLM; EICOM). Microdialysis buffer was
aCSF (perfusion buffer in mM: 1.3 CaCl2, 1.2 MgSO4, 3
KCl, 0.4 KH2PO4, and 122 NaCl, pH 7.35) containing
0.15-2 % BSA (Sigma-Aldrich) that was filtered through a
0.1 μMmembrane. The flow rate was 1.0 μL/min. Samples
were collected every 60 or 90 min into a refrigerated frac-
tion collector (Univentor Limited) in polypropylene tubes
and assessed for Aβx-40 by sandwich ELISA. Basal ISF Aβ
levels were defined as the mean concentration of Aβ over
the 9 h preceding drug administration. All Aβ values were
normalized to the basal Aβ concentration for each animal.
After establishing baseline ISF Aβ, pharmaceutical agents
(serotonin, 5-HTR agonists, 5-HTR antagonists, enzyme
inhibitors) were diluted in microdialysis perfusion buffer
and infused directly into the hippocampus by reverse
microdialysis (Table 1).
Aβ sandwich ELISA
ISF Aβx-40 levels were measured using sandwich ELISAs
as described [12]. This ELISA detects both human and
murine Aβ. A mouse anti-Aβ40 antibody (mHJ2; 10 μg/
ml) against the C-terminus of Aβ was used to capture
peptides and a biotinylated central domain antibody
(mHJ5.1; 75 ng/ml) was used to detect them. This was
followed by a streptavidin poly-HRP-40 assay to measure
Aβ concentration (Fitzgerald Industries). All steps in-
cluded washes with PBS containing 0.05 % Tween-20.
The standard curve for the ELISA was synthetic Aβ40
(American Peptide) taken from a stock in formic acid to
remove preformed aggregates. ELISA sample buffers in-
cluded sufficient Tris to neutralize pH of the formic
acid. To detect Aβ oligomers, ELISA plates were coated
a mouse anti-Aβ antibody (mHJ3.4; 10 μg/ml) to capture
of N-terminus of the peptide then detected using the same
monoclonal antibody that was biotinylated (500 ng/ml).
None of the buffers for this assay contain detergents as
such agents can artificially produce Aβ aggregates. The
standard curve for this ELISA is a synthetic dimer of hu-
man Aβ40 that contains a Ser26Cys mutation that enables
us to covalently crosslink the peptides together. The dimer
is then specifically isolated by size exclusion chromatog-
raphy. Aβ dimers were a generous gift from Dr. David
Brody, Washington University. The oligomer assay is simi-
lar to one used in [69]. All ELISAs were developed using
Super Slow ELISA TMB (Sigma-Aldrich) and absorbance
read on a Bio-Tek Epoch plate reader at 650 nm.
Quantitative real-time PCR (qPCR)
2.5 month old APP/PS1 mice were given 10 mg/kg i.p.
injections of citalopram or PBS. Mice were sacrificed
16 h later, and their hippocampi were microdissected.
Total RNA were extracted using the RNeasy Mini kit
(Qiagen) and reverse transcribed using the High Capacity
cDNA Reverse Transcription kit (Life Technologies). Indi-
vidual primers were designed using Harvard Medical
School Primer Bank (http://pga.mgh.harvard.edu/primer-
bank/index.html) [70–72]. See Additional file 1 for primer
sequences and database identification numbers. qPCR was
performed using the Fast SYBR Green Master Mix (Ap-
plied Biosystems) in ABI 7900HT (Applied Biosystems)
with the default thermal cycling program. Dissociation
curves were analyzed following qPCR assay to confirm
primer efficacy. Endogenous mouse GAPDH was used as
a normalization reference. Relative mRNA levels were cal-
culated by comparative Ct method using the ABI 7900HT
Sequence Detection Systems version 2.0.5 and GenEx ver-
sion 5 software (MultiD analyses). Levels of each mRNA
were statistically compared to CaMKII mRNA levels,
which our previous studies have shown does not mediate
suppression of brain Aβ levels [38].
Fisher et al. Molecular Neurodegeneration  (2016) 11:45 Page 9 of 12
SDS-PAGE/western blot
ISF samples collected from 1,000 kDa MWCO microdi-
alysis probes (AtmosLM, Eicom) in APP/PS1 mice
treated with citalopram for 16 h were utilized for West-
ern blotting for soluble APP-α. Hippocampus from
APP/PS1 mice treated with citalopram for 16 h was
lysed in 1 % Triton X-100, 0.1 % SDS in PBS by sonic-
ation. 20 μg of total protein was loaded per lane on
SDS-PAGE gels. SDS-PAGE was performed using 4–12 %
Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA) under
reducing conditions with 24 μl of microdialysis sample
loaded into each lane. Samples were loaded onto the gels
in alternating basal and drug-treated samples. Nitrocellu-
lose blots were probed with either mouse-anti-human
APP antibody directed against the C-terminus of sAPP-α
(m6E10; BioLegend), rabbit-anti-ADAM10 antibody
(H-300; Santa Cruz Biotech), rabbit-anti-ADAM17
(Abcam), goat-anti-MMP2 (C-19; Santa Cruz Biotech),
or mouse-anti-GAPDH (Sigma-Aldrich) followed by
either a sheep-anti-mouse antibody (GE Life Sciences),
donkey-anti-rabbit antibody (Santa Cruz Biotech), or a
donkey-anti-goat antibody (Santa Cruz Biotech) conju-
gated to peroxidase. Bands were detected with Lumigen-
TMA6 (Amersham, Piscataway, NJ) and captured digitally
using the Kodak ImageStation 440CF. Densitometry was
performed using the Kodak 1D Image Analysis software.
Tissue protein levels were normalized to GAPDH for each
lane, then normalized to % vehicle for each blot, followed
by data from two blots being combined for analysis.
Statistical analysis
Data in figures are presented as mean ± SEM. All statis-
tical analysis was performed using Prism version 6.0 for
Windows (GraphPad). For analysis of microdialysis data
at endpoints, the final 3 data points for a given treat-
ment phase were averaged, and one-way ANOVA ana-
lyses were performed with Dunnett’s corrections for
multiple comparisons. Comparison of only two groups
was performed using a two-tailed, unpaired Student t-
test method. For qPCR analysis, mean levels of gene
expression were analyzed by one-way ANOVA with
Dunnett’s corrections for multiple comparisons. Values
were accepted as significant if p-value ≤ 0.05.
Additional file
Additional file 1: Supplemental Data and Primer Sequences. (DOCX 358 kb)
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